China-based Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA) has announced a strategic partnership with compatriot firm Getein Biotech Inc. (SHA: 603387) to manufacture and market COVID-19 antigen tests and other in vitro diagnostics (IVD) products. The collaboration aims to enhance the availability and accessibility of diagnostic tools in response to the ongoing pandemic.
Partnership Details
Under the agreement, Meihua will serve as Getein’s exclusive manufacturing and research and development (R&D) partner in North Jiangsu, focusing on the production of COVID-19 antigen tests. Meihua has established a brand new GMP-aligned workshop, which is expected to commence operations on January 16, 2023. Financial details of the partnership were not disclosed.
Company Profiles
Getein, a leading point-of-care test (POCT) manufacturer in China, provides advanced clinical diagnostic equipment and quantitative immune analyzers. Its product portfolio includes rapid detection kits for cardiac markers, blood cell reagents, quantitative immune analyzers, and automatic urine microscopy analyzers. Meihua, a disposable medical device maker and supplier, has over 20 products approved in the US and a business presence covering more than 30 countries. The company offers more than 800 products in China, further expanding its reach through this partnership.
Future Outlook
The strategic partnership between Meihua and Getein underscores the commitment of both companies to address the significant demand for COVID-19 diagnostic tools. By leveraging their respective strengths in manufacturing and R&D, Meihua and Getein are poised to make a meaningful impact on the global response to the pandemic. The collaboration is expected to enhance the availability of rapid and reliable diagnostic solutions, benefiting healthcare providers and patients alike.-Fineline Info & Tech
